Aspirin in Primary Prevention: Interview With Kausik Ray

Linda Brookes, MSc; Kausik Ray, MBChB, MD, MPhil


March 08, 2012

In This Article

A Best Evidence Interview With Kausik Ray, MBChB, MD, MPhil

The Best Evidence Study

Seshasai SR, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med. 2012;172:209-216.

About the Interviewee

Kausik Ray, MBChB, MD, MPhil, is professor of cardiovascular disease prevention and honorary consultant cardiologist at St. George's Hospital NHS Trust, University of London, London, England. He is a clinical cardiologist and cardiovascular epidemiologist with an interest in primary and secondary prevention of cardiovascular disease. His research interests focus on cardiometabolic risk, preventative cardiology, cardiovascular epidemiology, and clinical trials. He is a reviewer for the UK Medical Research Council and an external expert for the National Institute for Health and Clinical Excellence (NICE). He is a member of the European Atherosclerosis Society (EAS) consensus panel evaluating the role of plasma levels of LDL cholesterol (Lp[a]), HDL cholesterol, and triglycerides in the prevention of cardiovascular disease; an expert member of the EAS Therapeutics Committee; and a national lead or member of the steering committee of several large international trials looking at novel drug interventions.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.